ATE361318T1 - Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen - Google Patents

Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Info

Publication number: ATE361318T1
Authority: AT; Austria
Prior art keywords: april; taci; bcma; cell; agp
Prior art date: 2000-05-12

Application number

AT01935466T

Other languages

English (en)

Inventor

Lars Eyde Theill

Gang Yu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-12

Filing date

2001-05-14

Publication date

2007-05-15

2001-05-14 Application filed by Amgen Inc filed Critical Amgen Inc

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE361318T1 publication Critical patent/ATE361318T1/de

Links

230000004913 activation Effects 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 abstract 7
102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 abstract 7
102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 6
108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 6
BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 5
210000001744 T-lymphocyte Anatomy 0.000 abstract 5
201000010099 disease Diseases 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
101150052424 AGP3 gene Proteins 0.000 abstract 3
101000678193 Mus musculus Alpha-1-acid glycoprotein 3 Proteins 0.000 abstract 3
ULDWTSQHEYEWRZ-CBEYZXOKSA-N ansamitocinoside p-3 Chemical compound C(/[C@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)C(C)C)CC1=O)OC)=C\C=C(C)\CC(C=2)=CC(OC)=C(Cl)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ULDWTSQHEYEWRZ-CBEYZXOKSA-N 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 3
238000001727 in vivo Methods 0.000 abstract 3
230000001419 dependent effect Effects 0.000 abstract 2
230000028996 humoral immune response Effects 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
101100537522 Homo sapiens TNFSF13B gene Proteins 0.000 abstract 1
206010025323 Lymphomas Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT01935466T 2000-05-12 2001-05-14 Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen ATE361318T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20403900P	2000-05-12	2000-05-12
US21459100P	2000-06-27	2000-06-27

Publications (1)

Publication Number	Publication Date
ATE361318T1 true ATE361318T1 (de)	2007-05-15

Family

ID=26899121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01935466T ATE361318T1 (de)	2000-05-12	2001-05-14	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Country Status (10)

Country	Link
US (2)	US6774106B2 (de)
EP (1)	EP1280826B1 (de)
JP (1)	JP2003533218A (de)
AT (1)	ATE361318T1 (de)
AU (3)	AU2001263114A1 (de)
CA (1)	CA2408617A1 (de)
DE (1)	DE60128216T2 (de)
ES (1)	ES2287130T3 (de)
MX (1)	MXPA02011130A (de)
WO (2)	WO2001087977A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
US7217788B2 (en)	1996-03-14	2007-05-15	Human Genome Sciences, Inc.	Human tumor necrosis factor delta polypeptides
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR20090016772A (ko) *	1999-08-17	2009-02-17	바이오겐 아이덱 엠에이 인코포레이티드	Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) *	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP5062606B2 (ja) *	2000-02-16	2012-10-31	ジェネンテック，インコーポレイテッド	Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
US20040013674A1 (en) *	2001-04-27	2004-01-22	Christine Ambrose	Taci as an anti-tumor agent
US7371388B1 (en)	2000-05-04	2008-05-13	Human Genome Sciences, Inc.	Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60143798D1 (de)	2000-06-16	2011-02-17	Cambridge Antibody Tech	Immunspezifisch bindende antikörper gegen blys
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
EP2267015A3 (de) *	2000-08-18	2011-04-20	Human Genome Sciences, Inc.	Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002046231A2 (en) *	2000-12-07	2002-06-13	The University Of British Columbia	Caml-binding peptides
WO2002066516A2 (en) *	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
EP1401870A4 (de)	2001-05-24	2006-04-19	Human Genome Sciences	Antikörper gegen tumor necrosis factor delta (april)
KR100976743B1 (ko) *	2001-05-24	2010-08-19	지모제넥틱스, 인코포레이티드	Ｔａｃｉ-면역글로불린 융합 단백질
CN1636067A (zh) *	2001-08-03	2005-07-06	杰南技术公司	TACls和BR3多肽及其用途
CA2467521A1 (en) *	2001-11-16	2003-07-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
EP1551877A4 (de) *	2002-07-25	2006-01-18	Genentech Inc	Taci-antikörper und deren verwendung
AU2003284260B2 (en) *	2002-10-11	2010-06-03	Zymogenetics, Inc.	Production of homotrimeric fusion proteins
MXPA05007019A (es)	2002-12-30	2005-08-18	Amgen Inc	Terapia de combinacion con factores co-estimuladores.
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
AU2004256042A1 (en) *	2003-06-05	2005-01-20	Genentech, Inc.	BlyS antagonists and uses thereof
US20050118728A1 (en) *	2003-07-02	2005-06-02	Caldwell Kevin K.	Two-layer antibody capture system
AU2004315198A1 (en)	2004-01-29	2005-08-18	Genentech, Inc.	Variants of the extracellular domain of BCMA and uses thereof
AU2005305182A1 (en) *	2004-11-04	2006-05-18	Genentech, Inc.	Polypeptides that bind BAFF and/or APRIL
WO2006067210A1 (en)	2004-12-23	2006-06-29	Laboratoires Serono S.A.	Bcma polypeptides and uses thereof
AU2006278229B2 (en) *	2005-08-09	2011-10-27	Ares Trading S.A.	Methods for treating B-cell malignancies using TACI-Ig fusion molecule
WO2007019573A2 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en)	2005-10-13	2013-11-29	Human Genome Sciences Inc	Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
AU2006318539B2 (en) *	2005-11-23	2012-09-13	Genentech, Inc.	Methods and compositions related to B cell assays
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
KR20090016707A (ko)	2006-05-15	2009-02-17	아레스 트레이딩 에스.에이.	Ｔａｃｉｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
FI2061803T4 (fi) *	2006-08-28	2023-03-14		Process for the purification of fc-containing proteins
AU2007291282B2 (en) *	2006-08-28	2011-10-20	Ares Trading S.A.	Process for the purification of Fc-fusion proteins
PE20081140A1 (es) *	2006-10-25	2008-09-22	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
JP2011500715A (ja)	2007-10-16	2011-01-06	ザイモジェネティクス，インコーポレイテッド	自己免疫疾患の治療のためのＢＬｙＳ阻害剤および抗ＣＤ２０剤の組合せ
EP2219675B1 (de) *	2007-11-12	2013-10-23	Ares Trading S.A.	Formulierungen für taci-immunoglobulin-fusionsproteine
JP5739326B2 (ja)	2008-04-25	2015-06-24	ザイモジェネティクス，インコーポレイテッド	Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) *	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP4147719A1 (de) *	2009-03-02	2023-03-15	Aduro Biotech Holdings, Europe B.V.	Antikörper gegen einen proliferationsinduzierenden liganden (april)
CN102597268B (zh)	2009-09-03	2017-09-22	弗·哈夫曼-拉罗切有限公司	用于治疗、诊断和监控类风湿性关节炎的方法
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
US20130295672A1 (en) *	2010-09-10	2013-11-07	Consejo Superior De Investigaciones Científicas	Stem cell culture media and methods
EP2640750A1 (de) *	2010-11-16	2013-09-25	Boehringer Ingelheim International GmbH	Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
RU2013140975A (ru)	2011-02-28	2015-04-10	Дженентек, Инк.	Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res Munich Gmbh	Moléculas de unión para bcma y cd3
NL2011406C2 (en) *	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
KR20230004939A (ko)	2014-02-07	2023-01-06	맥마스터 유니버시티	3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
WO2016003876A1 (en)	2014-07-03	2016-01-07	Oklahoma Medical Research Foundation	Treatment of multiple sclerosis and neuromyelitis optica
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
ES2889906T3 (es)	2015-05-21	2022-01-14	Harpoon Therapeutics Inc	Proteínas de unión triespecíficas y usos médicos
MA43308A (fr)	2015-11-25	2018-10-03	Visterra Inc	Molécules d'anticorps se liant à april et leurs utilisations
CA3024723A1 (en)	2016-05-20	2017-11-23	Robert B. Dubridge	Single domain serum albumin binding protein
WO2017223111A1 (en)	2016-06-21	2017-12-28	Teneobio, Inc.	Cd3 binding antibodies
HRP20240767T1 (hr)	2016-09-14	2024-09-13	Teneoone, Inc.	Cd3 vezujuća antitijela
BR112019012354A2 (pt)	2016-12-21	2019-11-26	Teneobio, Inc.	anticorpos apenas de cadeia pesada anti-bcma
WO2018236995A2 (en) *	2017-06-20	2018-12-27	Dana-Farber Cancer Institute, Inc.	Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
CN110891971B (zh)	2017-06-20	2024-01-12	特尼奥生物股份有限公司	仅有重链的抗bcma抗体
CA3070468A1 (en) *	2017-09-01	2019-03-07	Dana-Farber Cancer Institute, Inc.	Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
JP7227630B2 (ja)	2017-10-12	2023-02-22	マックマスターユニバーシティー	Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
JP7084990B2 (ja)	2017-10-13	2022-06-15	ハープーンセラピューティクス，インク．	三重特異性タンパク質と使用方法
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
KR20250151605A (ko)	2018-06-01	2025-10-21	노파르티스 아게	Bcma에 대한 결합 분자 및 이의 용도
US11110123B2 (en)	2018-07-17	2021-09-07	Triumvira Immunologics Usa, Inc.	T cell-antigen coupler with various construct optimizations
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
CN113286817B (zh)	2018-09-25	2025-01-28	哈普恩治疗公司	Dll3结合蛋白及使用方法
AU2020252556B2 (en)	2019-04-05	2026-02-05	Teneobio, Inc.	Heavy chain antibodies binding to PSMA
TWI905099B (zh)	2019-05-21	2025-11-21	瑞士商諾華公司	Cd19 結合分子及其用途
CR20210622A (es)	2019-06-14	2022-06-27	Teneobio Inc	Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
BR112022011964A2 (pt) *	2019-12-17	2022-09-06	Shenzhen Feipeng Biological Therapy Co Ltd	Anticorpo de ligação a bcma e uso do mesmo
MX2022013453A (es)	2020-04-29	2022-11-16	Teneobio Inc	Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
BR112022022524A2 (pt)	2020-05-08	2022-12-13	Alpine Immune Sciences Inc	Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
KR20240037892A (ko)	2021-06-01	2024-03-22	트리움비라 이뮤놀로직스 유에스에이, 인크.	클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
US11453723B1 (en)	2021-06-25	2022-09-27	Mcmaster University	BCMA T cell-antigen couplers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4289872A (en)	1979-04-06	1981-09-15	Allied Corporation	Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US5229490A (en) *	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
DE69312700T2 (de)	1992-04-14	1998-02-19	Cornell Res Foundation Inc	Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en)	1996-03-18	2001-01-18	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
EP0939804B2 (de)	1996-10-25	2011-06-15	Human Genome Sciences, Inc.	NEUTROKIN alpha
AU5705898A (en)	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
JP2002517977A (ja)	1997-06-06	2002-06-18	リジェネロンファーマシューティカルズ，インコーポレイテッド	Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1998055620A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
US6171787B1 (en)	1997-06-26	2001-01-09	Abbott Laboratories	Member of the TNF family useful for treatment and diagnosis of disease
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CZ294615B6 (cs) *	1997-09-12	2005-02-16	Apotech R & D Sa	Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
AU9315298A (en)	1997-09-12	1999-03-29	Apotech S.A.	Kay - a novel immune system protein
US6297022B1 (en)	1997-10-08	2001-10-02	Smithkline Beecham Corporation	Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
WO1999026976A1 (en)	1997-11-26	1999-06-03	Eli Lilly And Company	Tnf ligand family gene
NZ504548A (en)	1997-12-03	2003-06-30	Genentech Inc	Polypeptides and nucleic acids encoding human chordin
AU2093499A (en)	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
AU2212299A (en)	1998-01-05	1999-07-26	Genentech Inc.	Compositions and methods for the treatment of tumor
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
SK288176B6 (sk)	1999-01-07	2014-04-02	Zymogenetics, Inc.	Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
WO2000068378A1 (en) *	1999-05-06	2000-11-16	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
KR20090016772A (ko) *	1999-08-17	2009-02-17	바이오겐 아이덱 엠에이 인코포레이티드	Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP5062606B2 (ja) *	2000-02-16	2012-10-31	ジェネンテック，インコーポレイテッド	Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用

2001
- 2001-05-14 EP EP01935466A patent/EP1280826B1/de not_active Expired - Lifetime
- 2001-05-14 WO PCT/US2001/015504 patent/WO2001087977A2/en not_active Ceased
- 2001-05-14 AT AT01935466T patent/ATE361318T1/de not_active IP Right Cessation
- 2001-05-14 WO PCT/US2001/015567 patent/WO2001087979A2/en not_active Ceased
- 2001-05-14 US US09/854,864 patent/US6774106B2/en not_active Expired - Fee Related
- 2001-05-14 AU AU2001263114A patent/AU2001263114A1/en not_active Abandoned
- 2001-05-14 CA CA002408617A patent/CA2408617A1/en not_active Abandoned
- 2001-05-14 MX MXPA02011130A patent/MXPA02011130A/es active IP Right Grant
- 2001-05-14 AU AU2001261557A patent/AU2001261557B2/en not_active Ceased
- 2001-05-14 US US09/855,158 patent/US20020086018A1/en not_active Abandoned
- 2001-05-14 JP JP2001585195A patent/JP2003533218A/ja not_active Withdrawn
- 2001-05-14 ES ES01935466T patent/ES2287130T3/es not_active Expired - Lifetime
- 2001-05-14 DE DE60128216T patent/DE60128216T2/de not_active Expired - Fee Related
- 2001-05-14 AU AU6155701A patent/AU6155701A/xx active Pending

Also Published As

Publication number	Publication date
WO2001087979A2 (en)	2001-11-22
WO2001087977A2 (en)	2001-11-22
US6774106B2 (en)	2004-08-10
MXPA02011130A (es)	2003-03-10
AU2001263114A1 (en)	2001-11-26
WO2001087979A3 (en)	2002-05-30
EP1280826B1 (de)	2007-05-02
US20020086018A1 (en)	2002-07-04
EP1280826A2 (de)	2003-02-05
DE60128216T2 (de)	2008-01-10
CA2408617A1 (en)	2001-11-22
US20020081296A1 (en)	2002-06-27
ES2287130T3 (es)	2007-12-16
WO2001087977A3 (en)	2002-06-20
DE60128216D1 (de)	2007-06-14
JP2003533218A (ja)	2003-11-11
AU2001261557B2 (en)	2005-06-30
AU6155701A (en)	2001-11-26

Legal Events

Date	Code	Title	Description
2007-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE361318T1 (de)	2007-05-15	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
EA200501810A1 (ru)	2006-06-30	Композиция конъюгированного лекарственного средства
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
FR2869231A1 (fr)	2005-10-28	Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
ATE293989T1 (de)	2005-05-15	Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
NZ592973A (en)	2013-01-25	Compositions and methods of using angiopoietin-like 4 protein
EP2447280A3 (de)	2012-06-20	VEGF Analoga und Verfahren zur Verwendung davon
TR200000913T2 (tr)	2001-01-22	Tıbbi maddeler
CO5611160A2 (es)	2006-02-28	Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
TR200103233T2 (tr)	2002-04-22	Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
FR14C0051I2 (fr)	2019-01-18	Dialkylfumarates pour le traitement de maladies autoimmunes
NZ707292A (en)	2017-06-30	Activin-actrii antagonists and uses for increasing red blood cell levels
DE69830404D1 (de)	2005-07-07	P38-inhibitoren
CY1116107T1 (el)	2017-02-08	Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DK0839026T3 (da)	2002-01-21	Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
DK0609280T3 (da)	1999-10-25	Humane IL-3 varianter
NO971341D0 (no)	1997-03-21	Promoter for reseptor tyrosinkinase TIE
ATE543491T1 (de)	2012-02-15	Kombinationspräparat enthaltend ibuprofen und paracetamol
ATE411981T1 (de)	2008-11-15	Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE286074T1 (de)	2005-01-15	Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
EA200601288A1 (ru)	2006-12-29	Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
BR0305018A (pt)	2004-09-21	Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
WO2005009366A3 (en)	2005-07-28	Restoring vascular function
MXPA02005069A (es)	2003-09-25	Agentes de enlace especificos para t3 y metodos para su uso.
ATE386050T1 (de)	2008-03-15	Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden